Form 8-K - Current report:
SEC Accession No. 0001657312-25-000016
Filing Date
2025-04-29
Accepted
2025-04-29 06:07:04
Documents
15
Period of Report
2025-04-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vrna-20250429.htm   iXBRL 8-K 39057
2 EX-99.1 a20250429vrna-q1xpressrele.htm EX-99.1 82818
6 GRAPHIC new_veronacorpxlogoxinline.jpg GRAPHIC 394217
  Complete submission text file 0001657312-25-000016.txt   769164

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vrna-20250429.xsd EX-101.SCH 1785
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vrna-20250429_lab.xml EX-101.LAB 22332
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vrna-20250429_pre.xml EX-101.PRE 12988
17 EXTRACTED XBRL INSTANCE DOCUMENT vrna-20250429_htm.xml XML 2783
Mailing Address 3 MORE LONDON RIVERSIDE LONDON X0 SE1 2RE
Business Address 3 MORE LONDON RIVERSIDE LONDON X0 SE1 2RE 011-44-0-2032834200
Verona Pharma plc (Filer) CIK: 0001657312 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38067 | Film No.: 25882483
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)